{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:53Z","timestamp":1761058673553,"version":"3.33.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1007\/s11894-004-0038-x","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T22:51:36Z","timestamp":1179615096000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel therapies for pancreatic adenocarcinoma"],"prefix":"10.1007","volume":"6","author":[{"given":"Simona M.","family":"Pino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Q.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl 1","key":"38_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","volume":"53","author":"A Jemal","year":"2003","unstructured":"Jemal A, Murray T, Samuels A: Cancer statistics, 2003. CA Cancer J Clin 2003, 53(Suppl 1):5\u201326.","journal-title":"CA Cancer J Clin"},{"key":"38_CR2","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","volume":"358","author":"JP Neoptolemos","year":"2001","unstructured":"Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001, 358:1576\u20131585.","journal-title":"Lancet"},{"key":"38_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(01)06666-1","volume":"358","author":"RA Abrams","year":"2001","unstructured":"Abrams RA, Lillemoe KD, Plantadosi S: Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001, 358:1565\u20131566.","journal-title":"Lancet"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403\u20132413. This trial established gemcitabine as the standard treatment for advanced pancreatic cancer. The study used clinical benefit response as its primary objective.","journal-title":"J Clin Oncol"},{"key":"38_CR5","first-page":"1","volume":"4","author":"D Von Hoff","year":"2001","unstructured":"Von Hoff D, Mahadevan D, Bearss D: New developments in the treatment of patients with pancreatic cancer. Clin Oncol Updates 2001, 4:1\u201315.","journal-title":"Clin Oncol Updates"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/bjc.1994.24","volume":"69","author":"M Lohr","year":"1994","unstructured":"Lohr M, Trautmann B, Gottler M, et al.: Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer 1994, 69:144\u2013151.","journal-title":"Br J Cancer"},{"key":"38_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/370061a0","volume":"370","author":"H Sato","year":"1994","unstructured":"Sato H, Takino T, Okada Y, et al.: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994, 370:61\u201365.","journal-title":"Nature"},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","volume":"19","author":"SR Bramhall","year":"2001","unstructured":"Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447\u20133455. This definitive trial proved that marimastat was not effective for treatment of pancreatic cancer.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"38_CR9","first-page":"61","volume":"87","author":"SR Bramhall","year":"2002","unstructured":"Bramhall SR, Schulz J, Nemunaitis J, et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87(Suppl 2):61\u2013167.","journal-title":"Br J Cancer"},{"key":"38_CR10","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","volume":"21","author":"MJ Moore","year":"2003","unstructured":"Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296\u20133302. This trial demonstrated that the addition of gemcitabine to the matrix metalloproteinase inhibitor BAY 12-9566 did not improve survival in patients with advanced pancreatic cancer.","journal-title":"J Clin Oncol"},{"key":"38_CR11","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2001.19.15.3445","volume":"19","author":"KR Hess","year":"2001","unstructured":"Hess KR, Abbruzzese JL: Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol 2001, 19:3445\u20133446. This commentary provided a critical analysis of the clinical trials for matrix metalloproteinase inhibitors.","journal-title":"J Clin Oncol"},{"key":"38_CR12","first-page":"545","volume":"143","author":"RH Hruban","year":"1993","unstructured":"Hruban RH, Van Mansfeld AD, Offerhaus GJ, et al.: K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993, 143:545\u2013554.","journal-title":"Am J Pathol"},{"key":"38_CR13","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","volume":"93","author":"AA Adjei","year":"2001","unstructured":"Adjei AA: Blocking oncogenic ras signalling for cancer therapy. J Natl Cancer Inst 2001, 93:1062\u20131074.","journal-title":"J Natl Cancer Inst"},{"key":"38_CR14","doi-asserted-by":"publisher","first-page":"8323","DOI":"10.1073\/pnas.86.21.8323","volume":"86","author":"PJ Casey","year":"1989","unstructured":"Casey PJ, Solski PA, Der CJ, et al.: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A 1989, 86:8323\u20138327.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38_CR15","first-page":"608","volume":"20","author":"C Lersch","year":"2001","unstructured":"Lersch C, Van Cutsem E, Amado R, et al.: Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas [abstract]. Proc ASCO 2001, 20:608.","journal-title":"Proc ASCO"},{"key":"38_CR16","first-page":"548","volume":"21","author":"JS Macdonald","year":"2002","unstructured":"Macdonald JS, Chansky K, Whitehead R, et al.: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG) [abstract]. Proc ASCO 2002, 21:548.","journal-title":"Proc ASCO"},{"key":"38_CR17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2003.08.040","volume":"21","author":"SJ Cohen","year":"2003","unstructured":"Cohen SJ, Ho L, Ranganathan S, et al.: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003, 21:1301\u20131306. This trial demonstrated lack of efficacy of R115777 and provided surrogate marker analysis indicating that Ras was partially inhibited.","journal-title":"J Clin Oncol"},{"key":"38_CR18","first-page":"517","volume":"21","author":"E Van Cutsem","year":"2002","unstructured":"Van Cutsem E, Karasek P, Oettle H, et al.: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) [abstract]. Proc ASCO 2002, 21:517.","journal-title":"Proc ASCO"},{"key":"38_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.35642","volume":"29","author":"CL Arteaga","year":"2002","unstructured":"Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29:3\u20139. A well-written comprehensive review that summarized the biology of EGFR and novel approaches to targeting it.","journal-title":"Semin Oncol"},{"key":"38_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C","volume":"72","author":"H Funatomi","year":"1997","unstructured":"Funatomi H, Itakura J, Ishiwata T, et al.: Amphiregulin antisense oligonucleotide inhibits growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptortargeted therapy. Int J Cancer 1997, 72:512\u2013517.","journal-title":"Int J Cancer"},{"key":"38_CR21","first-page":"511","volume":"1","author":"JD Sato","year":"1983","unstructured":"Sato JD, Kawamoto T, Le AD, et al.: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1:511\u2013529.","journal-title":"Mol Biol Med"},{"key":"38_CR22","first-page":"747","volume":"6","author":"J Mendelsohn","year":"2000","unstructured":"Mendelsohn J: Blockade of receptors for growth factors: an anticancer therapy: the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000, 6:747\u2013753. In this lecture, Mendelsohn summarized the discovery of a monoclonal antibody against EGFR, cetuximab (IMC-C225), as a potential therapy for cancer.","journal-title":"Clin Cancer Res"},{"key":"38_CR23","first-page":"1936","volume":"6","author":"CJ Bruns","year":"2000","unstructured":"Bruns CJ, Harbison MT, Davis DW, et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000, 6:1936\u20131948. This study described the mechanism of action of C225.","journal-title":"Clin Cancer Res"},{"key":"38_CR24","first-page":"2926","volume":"60","author":"CJ Bruns","year":"2000","unstructured":"Bruns CJ, Solorzano CC, Harbison MT, et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60:2926\u20132935. One of the early publications indicating that the antiangiogenesis property of COX-2 inhibition contributed to the antitumor activity of COX-2 inhibitors.","journal-title":"Cancer Res"},{"key":"38_CR25","first-page":"518","volume":"20","author":"J Abbruzzese","year":"2001","unstructured":"Abbruzzese J, Rosenberg A, Xiong Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20:518.","journal-title":"Proc ASCO"},{"key":"38_CR26","first-page":"517","volume":"20","author":"H Safran","year":"2001","unstructured":"Safran H, Ramanathan RK, Schwartz J, et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER2\/neu [abstract]. Proc ASCO 2001, 20:517.","journal-title":"Proc ASCO"},{"key":"38_CR27","first-page":"4544s","volume":"6","author":"LM Greenberger","year":"2000","unstructured":"Greenberger LM, Discafani C, Wang YF, et al.: EKB-569: a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer [abstract]. Clin Cancer Res 2000, 6:4544s.","journal-title":"Clin Cancer Res"},{"key":"38_CR28","first-page":"788","volume":"22","author":"JA Morgan","year":"2003","unstructured":"Morgan JA, Bukowski RM, Xiong H, et al.: Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer [abstract]. Proc ASCO 2003, 22:788.","journal-title":"Proc ASCO"},{"key":"38_CR29","first-page":"4356","volume":"59","author":"MA Molina","year":"1999","unstructured":"Molina MA, Sitja-Arnau M, Lemoine MG, et al.: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal antiinflammatory drugs. Cancer Res 1999, 59:4356\u20134362.","journal-title":"Cancer Res"},{"key":"38_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/carcin\/21.2.139","volume":"21","author":"MT Yip-Schneider","year":"2000","unstructured":"Yip-Schneider MT, Barnard DS, Billings SD, et al.: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000, 21:139\u2013146.","journal-title":"Carcinogenesis"},{"key":"38_CR31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0022-3565(24)29465-9","volume":"298","author":"MT Yip-Schneider","year":"2001","unstructured":"Yip-Schneider MT, Sweeney CJ, Jung SH, et al.: Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001, 298:976\u2013985.","journal-title":"J Pharmacol Exp Ther"},{"key":"38_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1091-255X(02)00156-7","volume":"7","author":"MT Yip-Schneider","year":"2003","unstructured":"Yip-Schneider MT, Wiesenauer CA, Schmidt CM: Inhibition of the phosphatidylinositol 3\u2019-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 2003, 7:354\u2013363.","journal-title":"J Gastrointest Surg"},{"key":"38_CR33","first-page":"1306","volume":"60","author":"JL Masferrer","year":"2000","unstructured":"Masferrer JL, Leahy KM, Koki AT, et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306\u20131311.","journal-title":"Cancer Res"},{"key":"38_CR34","first-page":"625","volume":"62","author":"KM Leahy","year":"2002","unstructured":"Leahy KM, Ornberg RL, Wang Y, et al.: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62:625\u2013631.","journal-title":"Cancer Res"},{"key":"38_CR35","first-page":"448","volume":"21","author":"HQ Xiong","year":"2002","unstructured":"Xiong HQ, Du M, Wolff RA, et al.: Parmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer [abstract]. Proc ASCO 2002, 21:448.","journal-title":"Proc ASCO"},{"key":"38_CR36","first-page":"1502","volume":"22","author":"SE Smith","year":"2003","unstructured":"Smith SE, Burris HA, Loehrer PJ, et al.: Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer [abstract]. Proc ASCO 2003, 22:1502.","journal-title":"Proc ASCO"},{"key":"38_CR37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182\u20131186. The first presentation of the original hypothesis for the dependence of solid tumors on angiogenesis.","journal-title":"N Engl J Med"},{"key":"38_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","volume":"48","author":"AC Koong","year":"2000","unstructured":"Koong AC, Mehta VK, Le QT, et al.: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000, 48:919\u2013922.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"38_CR39","first-page":"1037","volume":"22","author":"HL Kindler","year":"2003","unstructured":"Kindler HL, Ansari R, Lester E, et al.: Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC) [abstract]. Proc ASCO 2003, 22:1037.","journal-title":"Proc ASCO"},{"key":"38_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0002-9440(10)61708-7","volume":"159","author":"F Chen","year":"2001","unstructured":"Chen F, Castranova V, Shi X: New insights into the role of nuclear factor B in cell growth regulation. Am J Pathol 2001, 159:387\u2013397.","journal-title":"Am J Pathol"},{"key":"38_CR41","first-page":"119","volume":"59","author":"W Wang","year":"1999","unstructured":"Wang W, Abbruzzese JL, Evans DB, et al.: The nuclear factor B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999, 59:119\u2013127.","journal-title":"Clin Cancer Res"},{"key":"38_CR42","first-page":"379","volume":"21","author":"DP Ryan","year":"2002","unstructured":"Ryan DP, Elder JP, Winkelmann J, et al.: Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors [abstract]. Proc ASCO 2002, 21:379.","journal-title":"Proc ASCO"},{"key":"38_CR43","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E","volume":"88","author":"JP Goeze","year":"2000","unstructured":"Goeze JP, Nielsen FC, Burcharth F, et al.: Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000, 88:2487\u20132494.","journal-title":"Cancer"},{"key":"38_CR44","first-page":"880","volume":"56","author":"SA Watson","year":"1996","unstructured":"Watson SA, Michaeli D, Grimes S, et al.: Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 1996, 56:880\u2013885.","journal-title":"Cancer Res"},{"key":"38_CR45","first-page":"533","volume":"20","author":"AD Gilliam","year":"2001","unstructured":"Gilliam AD, Henwood M, Watson SA, et al.: G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma [abstract]. Proc ASCO 2001, 20:533.","journal-title":"Proc ASCO"},{"key":"38_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/oli.1.1996.6.145","volume":"6","author":"ST Crooke","year":"1996","unstructured":"Crooke ST: Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev 1996, 6:145\u2013147.","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"38_CR47","doi-asserted-by":"crossref","first-page":"19954","DOI":"10.1016\/S0021-9258(19)88650-7","volume":"267","author":"BP Monia","year":"1992","unstructured":"Monia BP, Johnston DJ, Ecker DJ, et al.: Selective inhibition of mutant H-ras mRNA expression by antisense oligonucleotides. J Biol Chem 1992, 267:19954\u201319962.","journal-title":"J Biol Chem"},{"key":"38_CR48","doi-asserted-by":"publisher","first-page":"28259","DOI":"10.1074\/jbc.271.45.28259","volume":"271","author":"G Chen","year":"1996","unstructured":"Chen G, Oh S, Monia BP, et al.: Antisense oligonucleotides demonstrate a dominant role of c-Ki-ras proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996, 271:28259\u201328265.","journal-title":"J Biol Chem"},{"key":"38_CR49","first-page":"1038","volume":"22","author":"PA Burch","year":"2003","unstructured":"Burch PA, Alberts SR, Schroeder MT, et al.: Gemcitabine and ISIS-2504 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc ASCO 2003, 22:1038.","journal-title":"Proc ASCO"},{"key":"38_CR50","first-page":"555","volume":"9","author":"JR Hecht","year":"2003","unstructured":"Hecht JR, Bedford R, Abbruzzese JL, et al.: A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003, 9:555\u2013561.","journal-title":"Clin Cancer Res"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-004-0038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-004-0038-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-004-0038-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-004-0038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T13:46:57Z","timestamp":1737035217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-004-0038-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s11894-004-0038-x","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"type":"print","value":"1522-8037"},{"type":"electronic","value":"1534-312X"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}